Geldenhuys L - Search Results

1

Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma.

Baguma-Nibasheka M, Barclay C, Li AW, Geldenhuys L, Porter GA, Blay J, Casson AG, Murphy PR. Baguma-Nibasheka M, et al. Among authors: geldenhuys l. Mol Carcinog. 2007 Dec;46(12):971-80. doi: 10.1002/mc.20339. Mol Carcinog. 2007. PMID: 17477358

2

Microsatellite instability in esophageal adenocarcinoma.

Evans SC, Gillis A, Geldenhuys L, Vaninetti NM, Malatjalian DA, Porter GA, Guernsey DL, Casson AG. Evans SC, et al. Among authors: geldenhuys l. Cancer Lett. 2004 Aug 30;212(2):241-51. doi: 10.1016/j.canlet.2004.03.011. Cancer Lett. 2004. PMID: 15279904

3

Coexpression and regulation of the FGF-2 and FGF antisense genes in leukemic cells.

Baguma-Nibasheka M, Li AW, Osman MS, Geldenhuys L, Casson AG, Too CK, Murphy PR. Baguma-Nibasheka M, et al. Among authors: geldenhuys l. Leuk Res. 2005 Apr;29(4):423-33. doi: 10.1016/j.leukres.2004.09.006. Epub 2004 Dec 30. Leuk Res. 2005. PMID: 15725477

4

Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma.

Casson AG, Zheng Z, Evans SC, Geldenhuys L, van Zanten SV, Veugelers PJ, Porter GA, Guernsey DL. Casson AG, et al. Among authors: geldenhuys l. Cancer. 2005 Aug 15;104(4):730-9. doi: 10.1002/cncr.21229. Cancer. 2005. PMID: 15971196 Free article.

5

Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene.

Barclay C, Li AW, Geldenhuys L, Baguma-Nibasheka M, Porter GA, Veugelers PJ, Murphy PR, Casson AG. Barclay C, et al. Among authors: geldenhuys l. Clin Cancer Res. 2005 Nov 1;11(21):7683-91. doi: 10.1158/1078-0432.CCR-05-0771. Clin Cancer Res. 2005. PMID: 16278388

6

Alternative splicing of the FGF antisense gene: differential subcellular localization in human tissues and esophageal adenocarcinoma.

Zhang SC, Barclay C, Alexander LA, Geldenhuys L, Porter GA, Casson AG, Murphy PR. Zhang SC, et al. Among authors: geldenhuys l. J Mol Med (Berl). 2007 Nov;85(11):1215-28. doi: 10.1007/s00109-007-0219-9. Epub 2007 Jun 14. J Mol Med (Berl). 2007. PMID: 17569023

7

Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.

Vaninetti NM, Geldenhuys L, Porter GA, Risch H, Hainaut P, Guernsey DL, Casson AG. Vaninetti NM, et al. Among authors: geldenhuys l. Mol Carcinog. 2008 Apr;47(4):275-85. doi: 10.1002/mc.20382. Mol Carcinog. 2008. PMID: 17849424

8

Alternative splicing and differential subcellular localization of the rat FGF antisense gene product.

Zhang SC, MacDonald KA, Baguma-Nibasheka M, Geldenhuys L, Casson AG, Murphy PR. Zhang SC, et al. Among authors: geldenhuys l. BMC Mol Biol. 2008 Jan 23;9:10. doi: 10.1186/1471-2199-9-10. BMC Mol Biol. 2008. PMID: 18215310 Free PMC article.

9

Regulation of CDX2 expression in esophageal adenocarcinoma.

Vaninetti N, Williams L, Geldenhuys L, Porter GA, Guernsey DL, Casson AG. Vaninetti N, et al. Among authors: geldenhuys l. Mol Carcinog. 2009 Oct;48(10):965-74. doi: 10.1002/mc.20549. Mol Carcinog. 2009. PMID: 19415720

10

The role of scientific evidence in decisions to adopt complex innovations in cancer care settings: a multiple case study in Nova Scotia, Canada.

Urquhart R, Kendell C, Geldenhuys L, Ross A, Rajaraman M, Folkes A, Madden LL, Sullivan V, Rayson D, Porter GA. Urquhart R, et al. Among authors: geldenhuys l. Implement Sci. 2019 Feb 12;14(1):14. doi: 10.1186/s13012-019-0859-5. Implement Sci. 2019. PMID: 30755221 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

52 results

Search Page